It is firmly established that CD8+ T cells, M1-type macrophages, NK cells, and T follicular helper cells not only serve as instrumental agents in the immune clearance of tumor cells but also serve as indicative barometers of the potential efficacy of ICB therapy (47–52). The gene discussed is CD8A; the disease is neoplasm.